



# Repurposing a Generic Tuberculosis Vaccine to Treat Type 1 Diabetes



## Measuring CWR Success



In 2008, Cures Within Reach funded **Dr. Denise Faustman** at **Massachusetts General Hospital / Harvard** to support repurposing **the generic vaccine BCG** to help patients with **Type 1 Diabetes (T1D)**. CWR first funded a screening trial, then a Phase I clinical trial. In 2018, Faustman published long-term results from this Phase I clinical trial, showing that multi-dosing BCG in long-term T1D patients can result in stable and long-term correction of blood sugars with just two doses of BCG, without further intervention. Patients with longstanding T1D before the Phase I trial had lowered blood sugar levels nearing the normal range for 5 consecutive years, without changing their care routine (no new pumps or diabetes monitoring devices). CWR funds are now supporting the Phase II clinical trial with 150 longstanding T1D patients.



## KEY FACTS AND IMPACT

- CWR provided \$110,000 to fund the animal trial and Phase I / II human clinical trials repurposing the BCG vaccine for Type 1 Diabetes patients, along with funds from Iacocca Foundation.
- Phase I study resulted in long-term restoration of blood sugars in Type 1 diabetic patients.
- Early CWR funding helped to leverage **>\$20 million in follow-on funding** from the Iacocca Foundation needed for this FDA registration trial.
- Faustman has **expanded this BCG research to other diseases**, including COVID-19.

